Johnson & Johnson
-
Johnson vs. Johnson!
For more reports, please follow DrugTimes
-
【Product for Licensing】Johnson & Johnson just licensed in a STAT6 inhibitor. If you are interested in similar assets, please contact us asap
If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap
-
Johnson & Johnson to license novel oral assets, further strengthening commitment to atopic dermatitis
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
-
Split! Sanofi may book $16.4 billion
For more reports, please follow DrugTimes. Many thanks!
-
【重磅新闻】强生公司缩减心血管和代谢药物部门
药时代将继续关注，持续跟踪报道。
-
First! FDA approves new indication for Johnson & Johnson’s IL-23 antibody
Congratulations to Johnson & Johnson!
-
Breaking News! Legend Biotech’s CAR-T product “Ciltacabtagene Autoleucel” has been approved in China
Warmest congratulations to Legend Bio and JnJ!
-
Who will acquire Legend Bio for 13B to 15B USD? Could it be J&J?
Will J&J be the buyer? Please share your thoughts!~
